Cabaletta Bio, Inc. 8-K

What Happened

• On March 23, 2026, Cabaletta Bio, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company furnished a press release reporting those results as Exhibit 99.1 to the Form 8-K.
• The company also posted an updated corporate presentation in the “Investors & Media” section of its website (www.cabalettabio.com) and furnished that presentation as Exhibit 99.2. The Form 8-K was signed by CEO Steven Nichtberger.

Key Details

• Date filed: March 23, 2026 (Form 8-K).
• Reporting period: Q4 and fiscal year ended December 31, 2025.
• Materials provided: Press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2).
• Filed by: Cabaletta Bio, Inc.; signed by Steven Nichtberger, Chief Executive Officer.

Why It Matters

• This 8-K delivers the company’s official quarterly and year-end results and supporting investor materials; investors should review the press release and presentation for the specific financial metrics (revenue, net income/loss, cash position, and operational updates) that could affect valuation and near-term expectations.
• The updated corporate presentation may include refreshed strategy, program status, or financial highlights useful for evaluating Cabaletta’s progress and plans. Check the Exhibits and the Investors & Media page on Cabaletta’s website for full details.